| **DRUG (S)** | Alcortin-A (hydrocortisone/iodoquinol/aloe)  
Aloquin (aloe/iodoquinol) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POLICY #</strong></td>
<td>13145</td>
</tr>
</tbody>
</table>
| **INDICATIONS** | Based on a review of a related drug by the National Research Council and subsequent FDA classification for **Alcortin-A and Aloquin**, the indications are as follows: **Possibly** Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. 

Final classification of the less-than-effective indications requires further investigation. |
| **CRITERIA** | ConnectiCare considers **Alcortin and Aloquin** to be medically necessary when the following criteria are met:  

1. Patient is diagnosed with a corticosteroid responsive skin disorder  
   **AND**  
2. Patient has had adequate trials (of 2 weeks’ duration) of any **four** topical cortisone preparations  
   **AND**  
3. Patient has had adequate trials (of 2 weeks’ duration) of Ala-Quin (hydrocortisone/clioquinol) |
| **REFERENCES** | 1. Facts and Comparisons online  
2. Alcortin package insert, Novum Pharma, Chicago, IL  
3. Aloquin package insert, Novum Pharma, Chicago, IL |
| **P&T REVIEW HISTORY** | 2/17, 8/17, 7/18 |
| **REVISION RECORD** | |